<SEC-DOCUMENT>0001213900-24-108617.txt : 20241213
<SEC-HEADER>0001213900-24-108617.hdr.sgml : 20241213
<ACCEPTANCE-DATETIME>20241213082008
ACCESSION NUMBER:		0001213900-24-108617
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20241212
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20241213
DATE AS OF CHANGE:		20241213

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CHINA PHARMA HOLDINGS, INC.
		CENTRAL INDEX KEY:			0001106644
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				731564807
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34471
		FILM NUMBER:		241546875

	BUSINESS ADDRESS:	
		STREET 1:		2ND FLOOR, NO. 17, JINPAN ROAD
		STREET 2:		HAIKOU
		CITY:			HAINAN PROVINCE
		STATE:			F4
		ZIP:			570216
		BUSINESS PHONE:		8689866811730

	MAIL ADDRESS:	
		STREET 1:		2ND FLOOR, NO. 17, JINPAN ROAD
		STREET 2:		HAIKOU
		CITY:			HAINAN PROVINCE
		STATE:			F4
		ZIP:			570216

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TS ELECTRONICS INC
		DATE OF NAME CHANGE:	20030818

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SOFTSTONE INC
		DATE OF NAME CHANGE:	20030128

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SOFTSTONE INC /DE/
		DATE OF NAME CHANGE:	20010808
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea0224537-8k_china.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:CPHI="http://chinapharmaholdings.com/20241212">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_031_CPHI_chinapharmaholdings.com_20241212 -->
<!-- Field: Set; Name: xdx; ID: xdx_04F_20241212_20241212 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_057_edei%2D%2DEntityCentralIndexKey_0001106644 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2024-12-12" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-12-12" id="Fact000004" name="dei:EntityCentralIndexKey">0001106644</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="cphi-20241212.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2024-12-12">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-12-12</xbrli:startDate>
        <xbrli:endDate>2024-12-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_907_edei--DocumentType_c20241212__20241212_zZp8hGHZHU0h"><ix:nonNumeric contextRef="AsOf2024-12-12" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
<b><span id="xdx_906_edei--DocumentPeriodEndDate_c20241212__20241212_zfjNIzmvkr4b"><ix:nonNumeric contextRef="AsOf2024-12-12" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">December 12, 2024</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90B_edei--EntityRegistrantName_c20241212__20241212_zg1FrTjFW9qj"><ix:nonNumeric contextRef="AsOf2024-12-12" id="Fact000011" name="dei:EntityRegistrantName">CHINA PHARMA HOLDINGS, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of Registrant as specified in charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: white">
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--EntityIncorporationStateCountryCode_c20241212__20241212_zkjOINMVCZ6i"><ix:nonNumeric contextRef="AsOf2024-12-12" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_900_edei--EntityFileNumber_c20241212__20241212_zIJcOtcvOsBc"><ix:nonNumeric contextRef="AsOf2024-12-12" id="Fact000013" name="dei:EntityFileNumber">001-34471</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_906_edei--EntityTaxIdentificationNumber_c20241212__20241212_zJgMLqvQGrcb"><ix:nonNumeric contextRef="AsOf2024-12-12" id="Fact000014" name="dei:EntityTaxIdentificationNumber">73-1564807</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction </span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission File No.) </span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of Incorporation)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_90C_edei--EntityAddressAddressLine1_c20241212__20241212_z1JKQy4WhHbc"><ix:nonNumeric contextRef="AsOf2024-12-12" id="Fact000015" name="dei:EntityAddressAddressLine1">Second Floor</ix:nonNumeric></span>, <span id="xdx_903_edei--EntityAddressAddressLine2_c20241212__20241212_zzhdRTmXxxXg"><ix:nonNumeric contextRef="AsOf2024-12-12" id="Fact000016" name="dei:EntityAddressAddressLine2">No. 17, Jinpan Road</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_90B_edei--EntityAddressAddressLine3_c20241212__20241212_zbvpLQqVrWS5"><ix:nonNumeric contextRef="AsOf2024-12-12" id="Fact000017" name="dei:EntityAddressAddressLine3">Haikou</ix:nonNumeric></span>, <span id="xdx_90B_edei--EntityAddressCityOrTown_c20241212__20241212_zdwPid64RZod"><ix:nonNumeric contextRef="AsOf2024-12-12" id="Fact000018" name="dei:EntityAddressCityOrTown">Hainan Province</ix:nonNumeric></span>, <span id="xdx_900_edei--EntityAddressCountry_c20241212__20241212_zsYz6Gjme5o7"><ix:nonNumeric contextRef="AsOf2024-12-12" format="ixt-sec:countrynameen" id="Fact000019" name="dei:EntityAddressCountry">China</ix:nonNumeric></span> <span id="xdx_90F_edei--EntityAddressPostalZipCode_c20241212__20241212_zO5hUVEMhxra"><ix:nonNumeric contextRef="AsOf2024-12-12" id="Fact000020" name="dei:EntityAddressPostalZipCode">570216</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices) (Zip Code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number, including
area code: <b><span style="text-decoration: underline">+<span id="xdx_904_edei--CityAreaCode_c20241212__20241212_zcG9oys9t6X9"><ix:nonNumeric contextRef="AsOf2024-12-12" id="Fact000021" name="dei:CityAreaCode">86</ix:nonNumeric></span> <span id="xdx_904_edei--LocalPhoneNumber_c20241212__20241212_zearLsUiKhs2"><ix:nonNumeric contextRef="AsOf2024-12-12" id="Fact000022" name="dei:LocalPhoneNumber">898-6681-1730</ix:nonNumeric></span> (China)</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--WrittenCommunications_c20241212__20241212_zImwRqNrM9Wa"><ix:nonNumeric contextRef="AsOf2024-12-12" format="ixt:booleanfalse" id="Fact000023" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
communications pursuant to Rule 425 under the Securities Act (17CFR230.425)</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--SolicitingMaterial_c20241212__20241212_zMyNEWL9Ce55"><ix:nonNumeric contextRef="AsOf2024-12-12" format="ixt:booleanfalse" id="Fact000024" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
material pursuant to Rule14a-12 under the Exchange Act (17CFR240.14a-12)</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--PreCommencementTenderOffer_c20241212__20241212_zjtMikRFuMh5"><ix:nonNumeric contextRef="AsOf2024-12-12" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-2(b))</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--PreCommencementIssuerTenderOffer_c20241212__20241212_zj3rrBj3zI2d"><ix:nonNumeric contextRef="AsOf2024-12-12" format="ixt:booleanfalse" id="Fact000026" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR240.13e-4(c))</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section 12(b)
of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title of each class</b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading Symbol(s)</b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of each exchange on which registered</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--Security12bTitle_c20241212__20241212_zz6KY6x3A263"><ix:nonNumeric contextRef="AsOf2024-12-12" id="Fact000027" name="dei:Security12bTitle">Common Stock</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--TradingSymbol_c20241212__20241212_zSxmHiBoecx4"><ix:nonNumeric contextRef="AsOf2024-12-12" id="Fact000028" name="dei:TradingSymbol">CPHI</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--SecurityExchangeName_c20241212__20241212_zEV5ncvVnSvj"><ix:nonNumeric contextRef="AsOf2024-12-12" format="ixt-sec:exchnameen" id="Fact000029" name="dei:SecurityExchangeName">NYSE American</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <span id="xdx_90D_edei--EntityEmergingGrowthCompany_c20241212__20241212_zyvGm5LS4AYd"><ix:nonNumeric contextRef="AsOf2024-12-12" format="ixt:booleanfalse" id="Fact000030" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 1.01 Entry into a Material Definitive Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 12, 2024,
China Pharma Holdings Inc.. (the &#8220;<b>Company</b>&#8221;) entered into that certain securities purchase agreement (the
&#8220;<b>SPA</b>&#8221;) with certain institutional investor (the &#8220;<b>Investor</b>&#8221;) with respect to
an&#160;at-the-market&#160;offering under which the Investor may purchase, and the Company may sell within the commitment period
from December 12, 2024 to December 31, 2024, at the Investor&#8217;s sole discretion, shares of the Company&#8217;s common stock,
par value $0.001 per share (the &#8220;<b>Common Stock</b>&#8221;), having an aggregate offering price&#160;<span style="background-color: white">of
up to $600,000 (the &#8220;<b>Shares</b>&#8221;) <span style="background-color: white">(the &#8220;<b>Offering</b>&#8221;)</span>. Any Shares offered and sold in the Offering will be issued
pursuant</span>&#160;to the Company&#8217;s shelf Registration Statement on Form S-3 (File No. 333-276481) filed with the Securities
and Exchange Commission (the &#8220;<b>SEC</b>&#8221;) on January 12, 2024, as amended, which was declared effective on February 14,
2024, the related prospectus contained therein, and the prospectus supplement relating to the Offering filed with the SEC on
December 13, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Investor may acquire our
Common Stock through one or more closings upon our receipt of purchase notices. The number of our Common Stock will be determined based
on the at-the-market price equal to the lower of (i) the closing price the day prior to the purchase notice or (ii) the five (5) day average
closing prices as reported by Bloomberg or on the NYSE American Market&#8217;s website,
but in no event shall the per share price be lower than $0.15, which is to be stated in the purchase notice subject to repricing adjustments
as contemplated under the SPA as follows. In the event the Company&#8217;s delivery of the shares is not confirmed by 1:00 pm E.T. on
the trading day the purchase notice is submitted, the Investor has the right to adjust the purchase price to match the at-the-market price
on the date of the delivery of the purchase notice, which is only permitted if the market price on the delivery day is lower than the
previously established price. Further, the Investor, has the right, in its sole discretion, to return to the Company any or all the shares
issued under the SPA within one business day following the initial receipt of such shares and prior to the payment of the purchase price
to the Company if, based on price discovery or market conditions, the Investor determines that the issuance of such shares is unfavorable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, the Company
also provided &#8220;most favored nation&#8221; treatment (the &#8220;<b>MFN</b>&#8221;) to the Investor should the Company enter into
any financing, transaction, settlement, or similar agreement with more favorable terms within thirty (30) days after the effective date
of this SPA. In the event any of the forgoing events occurs during the term above referenced, such more favorable terms shall be retroactively
applied to all closed purchases and any future purchases under the SPA (the &#8220;<b>MFN Adjustments</b>&#8221;) as if the more favorable
terms had been in effect prior to each closing. MFN Adjustments may include but are not limited to, at-the-market price discounts, the
inclusion of warrants, or anti-dilution/true-up provisions. The difference in value from the MFN adjustments shall be issued to the Investor
as a convertible note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The actual proceeds to the
Company will vary depending on the number of shares sold and the prices of such sales. Because there is no minimum offering amount required
as a condition to close this offering, the actual total offering amount and proceeds to us, if any, are not determinable
at this time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The offering of our Common
Stock pursuant to the SPA will terminate on the earlier of (i) the date on which the Investor has purchased our Common Stock in a value
equal to $600,000, (ii) the date on which the Registration Statement is no longer effective, or (iii) December 31, 2024, unless extended
or terminated earlier in accordance with the terms of the SPA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing description
of the SPA is not complete and is qualified in its entirety by reference to the full text of the SPA, a copy of which is filed herewith
as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference. A copy of the opinion of Flangas Law Group
relating to the legality of the issuance and sale of the Shares in the Offering is attached as Exhibit 5.1 hereto.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Current Report on Form
8-K shall not constitute an offer to sell or the solicitation of an offer to buy the securities discussed herein, nor shall there be any
offer, solicitation, or sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 9.01 Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(d) Exhibits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: top; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit No.</b></span></td>
    <td style="padding-bottom: 1.5pt; white-space: nowrap; vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify; white-space: nowrap; vertical-align: bottom; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea022453701ex1-1_china.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of the Securities Purchase Agreement, dated December 12, 2024, by and between China Pharma Holdings Inc. and the
    Investor</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea022453701ex5-1_china.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Flangas Law Group</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea022453701ex99-1_china.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release Announcing the Entry of the At-the-Market Equity Financing</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: December 13, 2024</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td colspan="3"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CHINA PHARMA HOLDINGS, INC.</b></span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td colspan="3">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Zhilin Li</span></td></tr>
  <tr>
    <td style="vertical-align: top; width: 60%">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="vertical-align: top; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&#160; </span></td>
    <td style="vertical-align: top; width: 31%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Zhilin Li</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President and Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="text-align: center; margin-top: 0; margin-bottom: 0">3</p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->


<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjU0KwkAMhU/QO4RZiz9j3XSnRUWsIkXE7WBTGWwnJTNWPZK3NLaIIZCE974XpQZqTStbIcN5kWdwxLqpTEDIsURGd0FxpJttAjJzvFof2LjQnT8wJWFQmNlQxxcROmtrPRYJTPRIWseyJFMN852KvnpKrrQFumBNBcYVcGBq2GIw/OoTjuZJjupX9+qE7C05iRuOe/kNejzRsKfWPIhvHrIsVdGgq0itme6NuJbPgO5LwrLCWt75nv539AH8wUp7 -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>ea022453701ex1-1_china.htm
<DESCRIPTION>FORM OF THE SECURITIES PURCHASE AGREEMENT, DATED DECEMBER 12, 2024, BY AND BETWEEN CHINA PHARMA HOLDINGS INC. AND THE INVESTOR
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 1.1</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SECURITIES PURCHASE AGREEMENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">This Securities Purchase Agreement (this
&ldquo;Agreement&rdquo;) is made and entered into as of <B>December 12, 2024</B>, by and between <B>China Pharma Holdings, Inc. (CPHI)</B>
a Nevada corporation (the &ldquo;Company&rdquo;), and <B>[__________<FONT STYLE="font-family: Times New Roman, Times, Serif">]</FONT></B>
(the &ldquo;Purchaser&rdquo;). The Purchaser and the Company, each a &ldquo;<U>Party</U>&rdquo; and collectively, the &ldquo;<U>Parties</U>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">RECITALS</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>WHEREAS, </B>subject to the terms and conditions set forth in this
Agreement, the Company and the Purchaser desire to enter into this transaction to purchase the securities outlined herein under an effective
shelf registration statement on Form S-3 (Registration Number 333-276481) (the &ldquo;Registration Statement&rdquo;), which has at least
US$600,000 in unallocated securities registered thereunder. This Registration Statement has been declared effective in accordance with
the Securities Act of 1933, as amended (the &ldquo;1933 Act&rdquo;), by the United States Securities and Exchange Commission (the &ldquo;SEC&rdquo;).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>WHEREAS, </B>The Company desires to issue and sell to the Purchaser,
and the Purchaser desires to purchase from the Company shares of the Company&rsquo;s common stock, par value $0.001 per share (&ldquo;Common
Stock&rdquo;), and, as applicable, with an aggregate purchase amount of up to US$600,000.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>WHEREAS</B>, the Purchaser may acquire Common Stock through one
or more Closings by submitting one or more Purchase Notices (each, a &ldquo;Purchase Notice&rdquo;) based on the At-the-Market Price,
which shall be confirmed on the day prior to the designated Closing Date and subject to repricing adjustments as outlined in this Agreement;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>WHEREAS</B>, the Common Stock issued under this Agreement will be
registered for resale by the Purchaser under the Company&rsquo;s effective shelf registration statement filed with the United States Securities
and Exchange Commission (the &ldquo;Shelf Registration Statement&rdquo;);</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>WHEREAS</B>, each purchase of Common Stock will be limited to up
to 4.99% of the outstanding Common Stock, with any balance exceeding such percentage acquired in a manor to be mutually agreed upon by
the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOW, THEREFORE, </B>for good and valuable consideration,
the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ARTICLE I</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">DEFINITIONS</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For purposes of this Agreement, the following terms shall have the
meanings set forth below:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Affiliate&rdquo;</B> means any Person that, directly or indirectly
through one or more intermediaries, controls, is controlled by, or is under common control with a Person, as such terms are used in and
construed under Rule 405 of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><B>&ldquo;At The Market Value&rdquo;</B>
shall mean the lower of (i) the previous day&rsquo;s closing price or (ii) the five (5) day average closing price as reported by Bloomberg
or on the NYSE American Market&rsquo;s website and in accordance with NYSE Rule Section 312.03(c).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Base Prospectus&rdquo;</B> refers to the prospectus, dated
February 6, 2024, contained within the Registration Statement as filed with the U.S. Securities and Exchange Commission.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Beneficial Ownership Limitation&rdquo;</B> means a limitation,
not exceeding 4.99%, on the beneficial ownership of outstanding shares of Common Stock by the Purchaser immediately following a Closing.
Any shares in excess of this limit will be acquired in a manor to be mutually agreed upon by the Parties in writing and shall be incorporated
by reference as an amendment to the this agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Blanket Issuance Authorization&rdquo;</B> is an authorization
granted by the Company&rsquo;s board of directors permitting the issuance of shares up to the total number of Commitment Shares as outlined
in this Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Blanket Legal Opinion&rdquo;</B> is a legal opinion provided
by the Company&rsquo;s counsel confirming the eligibility of the Share Issuances under the effective Registration Statement and applicable
laws.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Business Day&rdquo;</B> means any day other than a Saturday,
Sunday, or other day on which commercial banks in New York City are authorized or required by law to close.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Closing&rdquo;</B> means the completion of each purchase
and sale of Common Stock pursuant to a Purchase Notice as described in Section 2.1.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Closing Date&rdquo; </B>refers to the date(s) by which the Purchaser&rsquo;s
payment obligation must be fulfilled, provided that the following conditions have been met: (i) execution of all Transaction Documents,
(ii) the Purchaser&rsquo;s submission of Exhibit A, the &ldquo;Purchase Notice,&rdquo; and (iii) the Company&rsquo;s delivery of shares
in accordance with the instructions provided on the preceding day.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Commitment Amount&rdquo;</B> is the total dollar amount of
the Company&rsquo;s Common Stock that the Purchaser commits to purchase under the terms of this Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Commitment Period&rdquo;</B> is the period beginning on the
Effective Date of this Agreement and ending on the earlier of (i) the date on which the Purchaser has purchased Common Stock equal to
the Maximum Commitment Amount, (ii) the date on which the Registration Statement is no longer effective, or (iii) December 31, 2024, unless
extended or terminated earlier in accordance with the terms of this Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Commission&rdquo;</B> means the United States Securities
and Exchange Commission.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Common Stock&rdquo;</B> means the Company&rsquo;s common
stock, par value $0.001 per share, and any class of securities into which such securities may hereafter be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Daily Penalty&rdquo;</B> has the meaning
set forth in <U>Section 2.3.5(a)</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Delivery Failure&rdquo;</B> refers to the failure of the
Company to deliver the Purchased Shares through DWAC within the specified time frame following the receipt of a valid Purchase Notice
from the Purchaser.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;DWAC&rdquo;</B> (Deposit/Withdrawal at Custodian) means the
electronic transfer system used to deposit and withdraw securities at The Depository Trust Company in accordance with the Company&rsquo;s
Transfer Agent instructions.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Effective Date&rdquo;</B> is the date on which this Agreement
is executed by both parties.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Exchange Act&rdquo;</B> refers to the Securities Exchange
Act of 1934, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Irrevocable Transfer Agent Instruction&rdquo; or &ldquo;ITAI&rdquo;</B>
refers to documented instructions that allow the Purchaser to direct the issuance and transfer of the Common Stock referenced in this
Agreement, held in the Share Reservation.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Medallion Signature Waiver&rdquo;</B> is a waiver that negates
the need for a Medallion Signature guarantee for the Purchaser when transferring shares, accompanied by an indemnity provision favoring
the Transfer Agent against any related claims.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Most Favored Nations Clause&rdquo;</B> refers to the provisions
granting the Purchaser certain rights in the event the Company grants more favorable terms to another party, as set forth in Section 4.2.1
of this Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Person&rdquo;</B> means an individual, corporation, partnership,
trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency
or subdivision thereof), or other entity of any kind.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Purchase Amount&rdquo;</B> means the total amount specified
by the Purchaser in each Purchase Notice, based on the At-the-Market Price.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Purchase Notice&rdquo;</B> refers to a formal notification
by the Purchaser to the Company specifying the number of shares to be purchased under the terms set forth in Exhibit A of this Agreement,
within the limitations of the Commitment Amount.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;RegSHO Short Sale&rdquo;</B> is the condition under which
the Purchaser is deemed to sell shares it does not yet own or has borrowed, complying with the regulations under Regulation SHO, including
marking requirements and applicable restrictions.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Reliance Letter&rdquo;</B> is a directive for the Transfer
Agent to rely on an external legal opinion regarding the validity of share issuances under this Agreement if deemed necessary by both
parties.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;SEC Required Filings&rdquo;</B> are the mandatory filings
that the Company must submit to the SEC, including but not limited to Forms 10-K, 10-Q, 8-K, and any other necessary documents.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Share Reservation&rdquo;</B> is the obligation for the Company
to reserve shares equivalent to the Commitment Amount within five (5) business days of signing this Agreement, confirmed by a receipt
from the Transfer Agent.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Securities Act&rdquo;</B> means the Securities Act of 1933,
as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Total Outstanding Shares&rdquo;</B> refers to the total number
of issued shares of the Company&rsquo;s Common Stock as verified by the Transfer Agent at the time of each issuance under this Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Trading Day&rdquo;</B> means any day on which the principal
Trading Market is open for trading.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Trading Market&rdquo;</B> means any of the markets or exchanges
on which the Common Stock is listed or quoted, including the NYSE American, or any other successor marketplace.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Transaction Documents&rdquo;</B> means this Agreement, the
Purchase Notice, the Share Reservation Instructions, the ITAI, the Blanket Opinion Letter, the Blanket Issuance Authorization, and the
Medallion Signature Waiver.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Transfer Agent&rdquo;</B> means Equiniti Trust Company.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><B>&ldquo;Total Outstanding Shares&rdquo;</B> means the total
number of issued and outstanding shares of the Company&rsquo;s Common Stock as verified by the Transfer Agent at the time of Closing pursuant
to this Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ARTICLE II</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">CLOSING AND SETTLEMENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0.25in; text-indent: 0pt">2.1. <FONT STYLE="font-size: 10pt">PURCHASE
AND SALE</FONT></P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-indent: -0.35in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">2.1.1.</TD><TD STYLE="text-align: justify">Timing of Delivery and Payment</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Closing of each transaction is initiated by a Purchase Notice and
shall occur on the following business day after the confirmed delivery of the Purchased Shares, marking the due date for the Purchase
Price to be paid to the Company by wire transfer, subject to any applicable price adjustments.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">2.1.2.</TD><TD STYLE="text-align: justify">Delivery of Shares</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company is required to deliver the Shares according to the DWAC
(Deposit/Withdrawal at Custodian) instructions specified in the Purchase Notice. Delivery shall be deemed complete when the Shares are
successfully transferred to the Purchaser&rsquo;s account per these instructions.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">2.1.3.</TD><TD STYLE="text-align: justify">Payment of Purchase Price</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Purchaser is required to pay the Purchase Price by Wire Transfer
on or before the Closing.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">2.1.4.</TD><TD STYLE="text-align: justify">Purchase Price Floor</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Notwithstanding anything to the contrary in this Agreement, the Purchaser
and the Company agree that no shares of the Company&rsquo;s Common Stock shall be sold or purchased under this Agreement at a price per
share below $0.15 (the &ldquo;Purchase Price Floor&rdquo;), unless mutually agreed in writing by both parties.</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-indent: -0.35in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">2.1.5.</TD><TD STYLE="text-align: justify">Purchase Price Adjustments</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If the Company&rsquo;s delivery of Common Stock, as per the Purchase
Notice, is not confirmed by 1 pm ET on the Trading Day it was submitted, the Purchaser has the right to adjust the purchase price listed
in Exhibit A to match the current At-the-Market price on the date of delivery. This adjustment is permitted only if the market price on
the delivery day is lower than the previously established price. The updated Exhibit A reflecting this adjustment must be submitted along
with the Wire Transfer Receipt.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">2.1.6.</TD><TD STYLE="text-align: justify">Delivery Failure</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A Delivery Failure occurs if the Company does not deliver the Shares
on the required date as specified in the Purchase Notice. In the event of a Delivery Failure, the Purchaser shall be entitled to the following
remedies:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a)</TD><TD STYLE="text-align: justify"><B>Daily Penalty for Delay:</B> A 4% daily penalty, calculated
based on the Notional Value of the undelivered Shares, shall accrue until the delivery obligation is fulfilled.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b)</TD><TD STYLE="text-align: justify"><B>Extended Delivery Failure:</B> If a Delivery Failure extends
beyond two (2) trading days, the Purchaser shall be entitled to additional compensation for any damages or trading losses directly resulting
from complications in trade settlement. The Purchaser may submit substantiated documentation, including but not limited to records of
broken trades, trade confirmations, and any other complications arising from the delay, along with a detailed accounting of fees and
losses incurred due to the extended Delivery Failure.</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0.25in; text-indent: 0pt">2.2. <FONT STYLE="font-size: 10pt">CONDITIONS
TO PURCHASER&rsquo;S CLOSING OBLIGATIONS</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Purchaser&rsquo;s obligation to purchase the Shares is subject
to the fulfillment of each of the following conditions at or prior to each Closing:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a)</TD><TD STYLE="text-align: justify"><B>Effectiveness of Registration Statement:</B> The Registration
Statement must be effective and must remain effective for the issuance of Shares as of each Closing Date, as well as the Company remaining
in good standing with all timely filings required by the SEC.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b)</TD><TD STYLE="text-align: justify"><B>Accuracy of Representations and Warranties:</B> All representations
and warranties made by the Company in this Agreement shall be true and correct in all material respects as of each Closing Date.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">c)</TD><TD STYLE="text-align: justify"><B>Performance of Covenants:</B> The Company shall have performed,
satisfied, and complied with all covenants, agreements, and conditions required by this Agreement in all material respects.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">d)</TD><TD STYLE="text-align: justify"><B>Executed Transaction Documents:</B> The Purchaser shall
have executed and delivered all required Transaction Documents and submitted a completed Exhibit A &ldquo;Purchase Notice.&rdquo;</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-indent: -0.3in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0.25in; text-indent: 0pt">2.3. <FONT STYLE="font-size: 10pt">CONDITIONS
TO COMPANY&rsquo;S CLOSING OBLIGATIONS</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company&rsquo;s obligation to issue and sell the Shares is subject
to the fulfillment of each of the following conditions at or prior to each Closing:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a)</TD><TD STYLE="text-align: justify"><B>Delivery of Purchase Price:</B> The Purchaser shall have
delivered the Purchase Price in accordance with the instructions provided by the Company.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b)</TD><TD STYLE="text-align: justify"><B>Accuracy of Representations and Warranties:</B> All representations
and warranties made by the Company in this Agreement shall be true and correct in all material respects as of each Closing Date.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">c)</TD><TD STYLE="text-align: justify"><B>Performance of Covenants:</B> The Purchaser shall have
performed, satisfied, and complied with all covenants, agreements, and conditions required by this Agreement in all material respects.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">d)</TD><TD STYLE="text-align: justify"><B>Submission of Purchase Notice:</B> The Purchaser shall
have submitted a completed Exhibit A &ldquo;Purchase Notice&rdquo; containing the total number of shares being acquired and the final terms
based on the At-the-Market purchase price.</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ARTICLE III</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">COVENANTS AND REPRESENTATIONS</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-indent: -0.3in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: left">3.1.
COMPANY COVENANTS AND REPRESENTATIONS</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The Company makes the following covenants and representations to the
Purchaser, acknowledging that the Purchaser is relying on these covenants and representations as a material inducement to enter into this
Agreement:</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-indent: -0.35in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">3.1.1.</TD><TD STYLE="text-align: justify">Corporate Status and Authorization</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The Company is duly organized, validly existing, and in good standing
under the laws of its jurisdiction of incorporation. The Company has all requisite corporate power and authority to enter into this Agreement,
perform its obligations hereunder, and consummate the transactions contemplated by this Agreement.</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-indent: -0.35in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.85in; text-indent: -0.35in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-align: justify; text-indent: -0.35in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">3.1.2.</TD><TD STYLE="text-align: justify">Valid Issuance</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The Shares to be issued under this Agreement will be, when issued and
delivered against payment in full as provided in this Agreement, duly authorized, validly issued, fully paid, non-assessable, and free
from all liens and encumbrances.</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-indent: -0.35in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">3.1.3.</TD><TD STYLE="text-align: justify">No Conflict</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The execution, delivery, and performance of this Agreement by the Company,
including the issuance of the Shares, will not result in (i) a violation of the Company&rsquo;s Certificate of Incorporation or Bylaws,
(ii) a breach of any agreement to which the Company is a party, or (iii) a violation of any law or governmental order applicable to the
Company.</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-indent: -0.35in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">3.1.4.</TD><TD STYLE="text-align: justify">SEC Compliance</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The Company is in compliance with all periodic reporting requirements
of the SEC under the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;). The Company has filed all reports required
to be filed under the Exchange Act and has not received any notification from the SEC or any other regulatory authority indicating any
deficiency in compliance with applicable regulations.</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-indent: -0.35in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">3.1.5.</TD><TD STYLE="text-align: justify">No Material Non-Public Information</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The Company represents that it has reviewed and understands the Purchaser&rsquo;s
&ldquo;Chinese Wall Policy&rdquo; and has not, and will not, disclose any Material Non-Public Information (MNPI) that could impact the Purchaser&rsquo;s
ability to trade the Company&rsquo;s stock. The Company shall promptly notify the Purchaser if it becomes aware of any inadvertent disclosure
of MNPI and take all necessary actions to remediate the disclosure.</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-indent: -0.35in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">3.1.6.</TD><TD STYLE="text-align: justify">Reservation of Shares</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The Company shall at all times maintain a reserve from its duly authorized
shares of Common Stock sufficient to enable the full issuance of the Commitment Amount under this Agreement.</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-indent: -0.35in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">3.1.7.</TD><TD STYLE="text-align: justify">Right to Return Shares</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Notwithstanding any other provision of this Agreement, the Purchaser
shall have the right, at its sole discretion, to return to the Company any or all Shares issued under this Agreement within 1 Business
Day following the initial receipt of such Shares and prior to Closing (the &ldquo;Return Period&rdquo;) if, based on price discovery or
market conditions, the Purchaser determines that the issuance of such Shares is unfavorable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>a.</B></TD><TD STYLE="text-align: justify"><B>Notice of Return:</B></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 1in">The Purchaser shall provide written notice to the Company during
the Return Period, specifying the number of Shares to be returned (the &ldquo;Returned Shares&rdquo;) and the basis for the return.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>b.</B></TD><TD STYLE="text-align: justify"><B>Effect of Return:</B></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 1in">Upon the Company&rsquo;s receipt of the Returned Shares, the
Company shall promptly cancel such Shares on its books and records.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The Purchaser shall be entitled to a credit or refund of the
corresponding Exercise Price or consideration paid for the Returned Shares, which shall be applied toward any future purchase obligations
or refunded to the Purchaser within [5] Business Days of the return.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>c.</B></TD><TD STYLE="text-align: justify"><B>Condition of Shares:</B></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 1in">The Returned Shares must be free of any encumbrances, liens,
or third-party claims arising from the Purchaser&rsquo;s actions, except as set forth in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>d.</B></TD><TD STYLE="text-align: justify"><B>Limitations:</B></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 1in">This clause shall not affect the Purchaser&rsquo;s rights or
obligations under this Agreement with respect to Shares that are not returned within the Return Period.</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-indent: -0.35in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.85in; text-indent: -0.35in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-align: justify; text-indent: -0.35in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">3.1.8.</TD><TD STYLE="text-align: justify">Compliance with Laws</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The Company shall comply with all applicable federal, state, and local
laws and regulations, including securities laws, and shall maintain all licenses and permits necessary to conduct its business.</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-indent: -0.35in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">3.1.9.</TD><TD STYLE="text-align: justify">No Violation of Others&rsquo; Rights</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The Company&rsquo;s execution and performance of this Agreement will
not conflict with or violate any rights of any third party, including creditors and shareholders of the Company, or result in the creation
of any lien or encumbrance on any assets or properties of the Company.</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-indent: -0.3in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-indent: 0in; text-align: justify">3.2.
PURCHASER COVENANTS AND REPRESENTATIONS</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The Purchaser makes the following covenants and representations to
the Company, acknowledging that the Company is relying on these covenants and representations as a material inducement to enter into this
Agreement:</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-indent: -0.35in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">3.2.1.</TD><TD STYLE="text-align: justify">Accredited Investor Status</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The Purchaser represents and warrants that it is an &ldquo;accredited
investor&rdquo; as defined in Rule 501(a) of Regulation D under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;),
or a &ldquo;qualified institutional buyer&rdquo; as defined in Rule 144A under the Securities Act.</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-indent: -0.35in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">3.2.2.</TD><TD STYLE="text-align: justify">Investment Intent</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The Purchaser is acquiring the Shares for its own account for investment
purposes only and not with a view to, or for sale in connection with, any distribution thereof within the meaning of the Securities Act.</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-indent: -0.35in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">3.2.3.</TD><TD STYLE="text-align: justify">Authority and Authorization</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The Purchaser has all necessary power and authority to enter into this
Agreement, perform its obligations hereunder, and consummate the transactions contemplated by this Agreement. This Agreement constitutes
the valid and binding obligation of the Purchaser, enforceable against it in accordance with its terms.</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-indent: -0.35in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">3.2.4.</TD><TD STYLE="text-align: justify">No Conflicts</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The execution, delivery, and performance of this Agreement by the Purchaser
do not (i) conflict with any governing documents of the Purchaser, (ii) breach any contract or agreement to which the Purchaser is a party,
or (iii) violate any applicable law or governmental regulation.</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-indent: -0.35in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.35in">3.2.5.</TD><TD STYLE="text-align: justify">Compliance with Securities Laws</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The Purchaser shall comply with all applicable securities laws in connection
with the purchase of Shares under this Agreement. The Purchaser represents that it understands the securities laws applicable to the purchase,
holding, and disposition of the Shares.</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-indent: -0.35in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">3.2.6.</TD><TD STYLE="text-align: justify">No Material Non-Public Information</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The Purchaser acknowledges that it is not receiving any Material Non-Public
Information (MNPI) from the Company or any representative of the Company and agrees not to solicit MNPI from the Company or its representatives.</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-indent: -0.35in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">3.2.7.</TD><TD STYLE="text-align: justify">Access to Information</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The Purchaser has had access to the Company&rsquo;s filings with the
SEC and has been afforded (i) the opportunity to ask such questions as it has deemed necessary of, and to receive answers from, representatives
of the Company concerning the terms and conditions of the Offering, (ii) access to information about the Company sufficient to enable
it to evaluate its investment, and (iii) the opportunity to obtain such additional information as it has deemed necessary to make an informed
investment decision.</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-indent: -0.35in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">3.2.8.</TD><TD STYLE="text-align: justify">No General Solicitation</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The Purchaser represents that it was not solicited by any form of general
solicitation or general advertising in connection with its purchase of the Shares, including, but not limited to, any advertisement, article,
notice, or other communication published in any newspaper, magazine, or similar media, or broadcast over television, radio, or the internet.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ARTICLE IV</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">RIGHTS AND ENTITLEMENTS</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-indent: -0.3in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-indent: 0in; text-align: justify">4.1.
COMPANY RIGHTS AND ENTITLEMENTS</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The Company shall have the following rights and entitlements under
this Agreement:</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-indent: -0.35in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">4.1.1.</TD><TD STYLE="text-align: justify">Right to Refuse Non-Compliance</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The Company reserves the right to refuse any Purchase Notice or other
instructions from the Purchaser if it determines, in good faith, that such notice or instruction does not comply with the terms of this
Agreement or applicable securities laws. The Company shall notify the Purchaser in writing of the basis for any such refusal within one
business day of receipt of the Purchase Notice.</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-indent: -0.35in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">4.1.2.</TD><TD STYLE="text-align: justify">Right to Monitor Purchaser Compliance</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The Company retains the right to verify the Purchaser&rsquo;s compliance
with applicable securities laws, including, but not limited to, determining the Purchaser&rsquo;s adherence to accreditation standards.
The Company shall conduct any such verification in a commercially reasonable manner and without undue interference with the Purchaser&rsquo;s
operations.</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-indent: -0.35in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">4.1.3.</TD><TD STYLE="text-align: justify">Right to Withdraw Registration Statement</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The Company reserves the right to withdraw or suspend the Registration
Statement at any time due to changes in applicable securities laws, regulatory orders, or significant corporate events, provided that
it notifies the Purchaser promptly and takes all reasonable actions to minimize any adverse effects on the Purchaser.</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-indent: -0.35in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">4.1.4.</TD><TD STYLE="text-align: justify">Right to Enforce Covenants</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The Company has the right to enforce all covenants and obligations
agreed upon by the Purchaser, including, but not limited to, representations regarding compliance with securities laws, confidentiality,
and adherence to the terms set forth in this Agreement.</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-indent: -0.35in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">4.1.5.</TD><TD STYLE="text-align: justify">Right to Cancel</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">In the event that the Purchaser fails to complete payment by the next
business day following confirmation of share delivery, the Company reserves the right to cancel the applicable Purchase Notice. Upon exercising
this Right to Cancel, the Purchaser is required to Reverse DWAC the Purchased Shares to the Company&rsquo;s Transfer Agent.</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-indent: -0.3in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-indent: 0in; text-align: justify">4.2.
PURCHASER RIGHTS AND ENTITLEMENTS</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The Purchaser shall have the following rights and entitlements under
this Agreement:</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-indent: -0.35in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">4.2.1.</TD><TD STYLE="text-align: justify">Most Favored Nations (MFN) Rights</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">For thirty (30) days following the Effective Date of this Agreement,
should the Company enter into any financing, transaction, settlement, or similar agreement with more favorable terms than those provided
to the Purchaser hereunder, such favorable terms shall be retroactively applied to all closed tranches and any future tranches within
the Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">a)</TD><TD STYLE="text-align: justify"><B>MFN Trigger and Trigger Date</B>: The MFN Rights are triggered if the Company enters into any transaction, settlement, or exchange
with terms that would have provided a more favorable economic outcome when adopting such terms in past Closings. The MFN Trigger Date
is the date of such transaction.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">b)</TD><TD STYLE="text-align: justify"><B>MFN Adjustments</B>: Any adjustment shall apply to past and, if applicable, future transactions as if the more favorable terms
had been in effect prior to each closing. Adjustments may include but are not limited to, At-The-Market price discounts, the inclusion
of warrants, or anti-dilution/true-up provisions.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">c)</TD><TD STYLE="text-align: justify"><B>Adjustment Mechanism</B>: The difference in value from the MFN adjustments shall be issued to the Purchaser as a Convertible Note
(the &ldquo;Adjustment Note&rdquo;). The Adjustment Note shall be calculated based on the notional value at each closing and shall include
any applicable Default Interest or Penalties.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-indent: -0.35in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.85in; text-indent: -0.35in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-align: justify; text-indent: -0.35in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">4.2.2.</TD><TD STYLE="text-align: justify">Adjustment Note</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Upon triggering the MFN clause, the Adjustment Note will be issued
to the Purchaser under the following conditions:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">a)</TD><TD STYLE="text-align: justify"><B>Adjustment Note Value Calculation</B>: The value of the Adjustment Note shall be determined by calculating the difference in the
economic value of any prior closings by including the more favorable terms in any and all prior closings, plus if applicable, any accrued
interest and penalties from the MFN Trigger Date until the time the Company has cured the defaults under the Adjustment Note.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">b)</TD><TD STYLE="text-align: justify"><B>Initial Terms:</B> The Adjustment Note shall initially be non-interest-bearing and convertible at the At-The-Market price. If the
current S3 registration lacks the capacity to register the Note, the Company must file an S-1 Registration Statement within twenty (20)
days of the MFN trigger date.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">c)</TD><TD STYLE="text-align: justify"><B>Failure to Register or File within Twenty (20) Business Days:</B> If the Company fails to file an S-1 Registration Statement within
twenty (20) days of the MFN Trigger Date, the Adjustment Note will accrue interest retroactively at an 8% per annum rate from the Trigger
Date. Additionally, it will become convertible at a 15% discount to the prevailing market price.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">d)</TD><TD STYLE="text-align: justify"><B>Failure to Register within Sixty (60) Business Days</B>: Should the Company fail to register the underlying Common Stock of the
Adjustment Note within sixty (60) Business Days of the MFN Trigger, a Failure to Register penalty equal to 8% of the Adjustment Note&rsquo;s
Current Value shall be added to the principal each week until the Adjustment Note is registered or fully converted into Common Stock by
the Purchaser.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">e)</TD><TD STYLE="text-align: justify"><B>Confession of Judgment:</B> The Adjustment Note shall include a Confession of Judgment, permitting the Purchaser to seek a legal
validation of any accrued fees, damages, or legal costs associated with enforcing the Purchaser&rsquo;s rights, if necessary.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">f)</TD><TD STYLE="text-align: justify"><B>Inclusion in Irrevocable Transfer Agent Instruction (ITAI): </B>The Adjustment Note will be included within the ITAI, enabling
the Purchaser to direct the Transfer Agent to reserve shares equivalent to the Adjustment Note balance, convert shares at its discretion,
and if unregistered, instruct the Transfer Agent to remove any restrictive legend per the Reliance Letter and accompanying legal opinion
on exemption from registration requirements.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-indent: -0.35in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">4.2.3.</TD><TD STYLE="text-align: justify">Notification Requirement</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The Company shall notify the Purchaser in writing within three (3)
Business Days of any Triggering Event that may impact the economic value or rights of prior closings, including any new securities issuance,
transaction, or material event that affects the terms of this Agreement.</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-indent: -0.35in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">4.2.4.</TD><TD STYLE="text-align: justify">Notification Penalty</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">In the event the Company fails to notify the Purchaser of a Triggering
Event, a 10% Default Penalty shall be applied to the Adjustment Note&rsquo;s Value.</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-indent: -0.35in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">4.2.5.</TD><TD STYLE="text-align: justify">Audit Right</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Purchaser shall have the right to audit the Company&rsquo;s compliance
with the Most Favored Nations (MFN) Clause. The Purchaser may request, and the Company shall promptly provide all relevant documents and
records necessary to verify compliance with the MFN terms.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ARTICLE V</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">MISCELLANEOUS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0pt">5.1. ARBITRATION</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Any dispute, controversy, or claim arising out of, relating to, or
in connection with this Agreement, including any question regarding its existence, validity, or termination, shall be resolved through
binding arbitration. The arbitration shall be conducted in Florida in accordance with the rules of the American Arbitration Association
(AAA) or JAMS then in effect. Judgment on the award rendered by the arbitrator(s) may be entered in any court having jurisdiction thereof.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0pt">5.2. LIMITATION
OF LIABILITY</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Each party&rsquo;s aggregate liability to the other party arising out of
or relating to this Agreement, whether in contract, tort (including negligence), breach of statutory duty, or otherwise, shall be limited
to the total dollar amount of the Commitment Amount specified in Section 1.11 of this Agreement. In no event shall either party be liable
to the other for any indirect, incidental, consequential, special, or punitive damages, including lost profits or business opportunities,
even if advised of the possibility of such damages.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0pt">5.3. GOVERNING
LAW</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">This Agreement shall be governed by and construed in accordance with
the laws of the State of Florida, without regard to its conflicts of law principles. Both parties agree to submit to the exclusive jurisdiction
of the state and federal courts located within the State of Florida for the purposes of enforcing any arbitration award under this Agreement
or for any other actions not subject to arbitration.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0pt">5.4. ENTIRE
AGREEMENT</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">This Agreement, together with all exhibits and schedules attached hereto,
constitutes the entire understanding between the parties with respect to the subject matter hereof, superseding all prior negotiations,
discussions, agreements, and understandings, whether written or oral. No modification, amendment, or waiver of any provision of this Agreement
shall be effective unless in writing and signed by both parties.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0pt">5.5. SEVERABILITY</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">If any provision or portion of this Agreement is found to be invalid,
illegal, or unenforceable in any jurisdiction, such invalidity, illegality, or unenforceability shall not affect any other term or provision
of this Agreement or invalidate or render unenforceable, such provision in any other jurisdiction. The remaining provisions of this Agreement
shall remain in full force and effect, and the invalid or unenforceable provision shall be amended or replaced by a valid, enforceable
provision that most closely achieves the parties&rsquo; original intent.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0pt">5.6. WAIVER</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">No waiver by either party of any breach or non-fulfillment of any provision
of this Agreement shall be deemed to be a waiver of any subsequent breach or non-fulfillment, and no waiver shall be effective unless
it is in writing and signed by the waiving party.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0pt">5.7. COUNTERPARTS</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">This Agreement may be executed in any number of counterparts, each
of which shall be deemed an original, and all of which together shall constitute one and the same instrument. Signatures delivered via
electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0pt">5.8. FORCE MAJEURE</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Neither party shall be liable for any delay or failure to perform its
obligations under this Agreement (except for payment obligations) if such delay or failure is due to events beyond the reasonable control
of the affected party, including acts of God, fire, flood, war, terrorism, government action, labor disputes, or other similar events.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.3in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0pt">5.9. NOTICES</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">All notices or other communications required or permitted under this
Agreement shall be in writing and shall be deemed effectively given (i) upon personal delivery to the party to be notified, (ii) when
sent by email or facsimile if sent during regular business hours of the recipient, or (iii) one (1) business day after deposit with a
reputable overnight courier, specifying next-day delivery, with written verification of receipt. Notices shall be sent to the respective
parties at the addresses set forth below or to such other address as may be designated by a party in writing.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0pt">5.10. HEADINGS</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The headings in this Agreement are included for convenience of reference
only and shall not affect the interpretation of this Agreement.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0pt">5.11. COUNTERPARTS;
ELECTRONIC SIGNATURES</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">This Agreement may be executed in any number of counterparts, each
of which shall be deemed an original and all of which together shall constitute one and the same agreement. A signed copy of this Agreement
delivered by facsimile, e-mail, or other electronic transmission shall be deemed to have the same legal effect as delivery of an original
signed copy of this Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">{Signature Page Follows}</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">IN WITNESS WHEREOF, the parties hereto have executed this Securities
Purchase Agreement as of the date first written above.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD COLSPAN="2">China Pharma Holdings, Inc.</TD><TD STYLE="text-align: justify">&nbsp;</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 5%">&nbsp;</TD><TD STYLE="text-align: left; width: 35%">&nbsp;</TD><TD STYLE="text-align: justify; width: 60%">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>By:</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>Name:&nbsp;</TD><TD STYLE="text-align: left">Zhilin Li</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>Title:</TD><TD STYLE="text-align: left">CEO &amp; Chairman</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD COLSPAN="2">Purchaser:</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 35%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD COLSPAN="2">[__________]</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>Name:&nbsp; </TD>
    <TD STYLE="text-align: left">[__________]</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>Title: </TD>
    <TD STYLE="text-align: left">[__________]</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Exhibits:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt">Exhibit A &ndash; Purchase Notice</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt">Exhibit B &ndash; Issuance Authorization</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt">Exhibit C - Irrevocable Transfer Agent Instruction Letter &amp;
Medallion Signature Waiver</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Exhibit D - Legal Opinion Letter</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">11</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>ea022453701ex5-1_china.htm
<DESCRIPTION>OPINION OF FLANGAS LAW GROUP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><I><SUP>FLG</SUP></I> <B>Flangas
Law Group</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Writer&rsquo;s email: kps@fdlawlv.com</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">December 12, 2024</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Equiniti Trust Company</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attn: Chad Dalton</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Transfer Department</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1110 Centre Pointe Curve, Suite 101</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mendota Heights, MN 55120</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">chad.dalton@equiniti.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Board of Directors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">China Pharma Holdings, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Second Floor, No. 17, Jinpan Road</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Haikou, Hainan Province, China 570216&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">Re:</TD><TD STYLE="text-align: justify">China Pharma Holdings, Inc.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have acted as special Nevada
counsel to China Pharma Holdings, Inc., a Nevada corporation (the <U>&ldquo;Company</U>&rdquo;), in connection with a Registration Statement
on Form S-3 (File No. 333-276481) (the &ldquo;<U>Registration Statement</U>&rdquo;), heretofore filed with the U.S. Securities and Exchange
Commission (the &ldquo;<U>SEC</U>&rdquo;) under the Securities Act of 1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;) and declared
effective by the SEC on February 14, 2024, with respect to the registration of up to $50,000,000 of any combination of (i) common stock,
par value $0.001 per share (the &ldquo;<U>Common Stock</U>&rdquo;), of the Company, (ii) preferred stock, par value $0.001 per share,
of the Company (the &ldquo;<U>Preferred Stock</U>&rdquo;), (iii) debt securities of the Company (the &ldquo;<U>Debt Securities</U>&rdquo;),
(iv) warrants to purchase Common Stock, Preferred Stock, Debt Securities or Units (as defined below) (&ldquo;<U>Warrants</U>&rdquo;),
(v) units comprised of Common Stock, Preferred Stock, Debt Securities and Warrants in any combination (&ldquo;<U>Units</U>&rdquo;) or
(vi) rights to purchase shares of Common Stock or Preferred Stock (&ldquo;<U>Rights</U>&rdquo;). The Common Stock, Preferred Stock, Warrants,
Debt Securities, Units and Rights are sometimes referred to collectively herein as the &ldquo;<U>Securities</U>.&rdquo; Securities may
be issued in an unspecified number (with respect to Common Stock, Preferred Stock, Warrants, Units and Rights) or in an unspecified principal
amount (with respect to Debt Securities). The Registration Statement provides that the Securities may be offered separately or together,
in separate series, in amounts, at prices and on terms to be set forth in one or more prospectus supplements (each a &ldquo;<U>Prospectus
Supplement</U>&rdquo;) to the prospectus contained in the Registration Statement. As of December 12, 2024, the Company has entered into
a Securities Purchase Agreement with Liqueous LP (the &ldquo;<U>Securities Purchase Agreement</U>&rdquo;) to purchase a total number of
up to 4,000,000 shares of Common Stock with an aggregate purchase amount of up to $600,000, not to exceed 20% of the outstanding Common
Stock. We are providing this letter to express our opinion confirming the eligibility of the issuance of the Common Stock pursuant to
the Securities Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">3275 South Jones Blvd., Suite 105 | Las Vegas, Nevada 89146 | Phone: (702) 307-9500 | Fax: (702) 382-9452</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">December 12, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page 2 of 4</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In arriving at the opinion
expressed below, we have examined such corporate proceedings, records and documents, and such matters of law, as we have considered necessary
for the purposes of this opinion. As to matters of fact, we have examined and relied upon the representations of the Company contained
in the Registration Statement and, where we have deemed appropriate, representations or certificates of officers of the Company or public
officials. As part of our examination, we have examined the following documents, among others:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A. the Registration Statement
(including the prospectus contained therein);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">B. the Securities Purchase
Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">C. the Articles of Incorporation
of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">D. the Bylaws of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">E. a Certificate of Good Standing
issued by the Secretary of State of the State of Nevada, dated December 11, 2024, certifying that the Company is in existence and in good
standing in the State of Nevada;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">F. certain resolutions of
the Board of Directors of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">L. certain certificates of
the officers of the Company certifying as to certain factual matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In rendering the opinion expressed
below, we have assumed without verification the genuineness of all signatures, the legal capacity of natural persons, the authenticity
of all documents submitted to us as originals, the conformity to the originals of all documents submitted to us as copies and the authenticity
of the originals of such copies, and the due authorization, execution and delivery of all documents by all parties and the validity, binding
effect and enforceability thereof (other than the authorization, execution and delivery of documents by the Company and the validity,
binding effect and enforceability thereof upon the Company). In addition, we have assumed and not verified the accuracy as to the factual
matters of each document we have reviewed and the accuracy of, and each applicable party&rsquo;s full compliance with, any representations
and warranties contained therein. Accordingly, we are relying upon (without any independent investigation thereof) the truth and accuracy
of the statements, covenants, representations and warranties set forth in the documents we have reviewed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based upon the foregoing and
subject to the assumptions, exceptions, limitations and qualifications set forth herein, we are of the opinion that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">1. The
Company is a corporation validly existing and in good standing under the laws of the state of Nevada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">December 12, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page 3 of 4</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">2. The
Securities Purchase Agreement has been duly authorized, executed and delivered by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">3. The
shares of Common Stock to be purchased pursuant to the Securities Purchase Agreement have been duly authorized for issuance and sale pursuant
to the Securities Purchase Agreement and, when issued and delivered by the Company pursuant to the Securities Purchase Agreement against
payment of the consideration set forth therein, will be validly issued, fully paid and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">4. The
execution and delivery of the Securities Purchase Agreement by the Company, and the performance by the Company of its obligations under
such agreement (other than performance by the Company of its indemnification obligations, as to which no opinion is rendered) will not
result in any (i) violation of the provisions of the Articles of Incorporation, as amended, or bylaws of the Company; (ii) conflict with
or result in a breach of any of the terms and provisions of, or constitute a default (or an event which with notice or lapse of time,
or both, would constitute a default) under, or result in the creation or imposition of any lien, charge or encumbrance upon any property
or assets of the Company or any of its subsidiaries pursuant to, any of the agreements (the &ldquo;Material Agreements&rdquo;) that are
exhibits contained in filings made by the Company pursuant to the Securities Exchange Act of 1934, as amended (the &ldquo;<U>Exchange
Act</U>&rdquo;), and incorporated by reference in the Registration Statement; or (iii) will not result in any violation of any federal
or Nevada law or, to our knowledge any administrative regulation or administrative or court decree, applicable to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">5.
No consent, approval, authorization or other order of, or registration or filing with, any
court or other governmental or regulatory authority or agency, is required for the consummation of the transactions contemplated by
the Securities Purchase Agreement, except such as have been obtained or made by the Company and are in full force and effect under
the Securities Act or applicable state securities or blue sky laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">6. To
our knowledge, the Company is not in violation of its Articles of Incorporation, as amended, or in default under any of the Material Agreements,
except for such violation or default as would not, individually or in the aggregate, result in a Material Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We render this opinion only
with respect to, and we express no opinion herein concerning the application or effect of the laws of any jurisdiction other than, the
existing laws of the state of Nevada. We express no opinion with respect to any other laws or with respect to the &ldquo;blue sky&rdquo;
securities laws of any state.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We render this opinion subject
to applicable bankruptcy, insolvency (including, without limitation, all laws relating to fraudulent transfer or conveyance), reorganization,
moratorium and other similar laws affecting creditors&rsquo; rights generally and to general principles of equity (regardless of whether
enforcement is sought in a proceeding in equity or at law), including, without limitation, (a) the possible unavailability of specific
performance, injunctive relief or any other equitable remedy and (b) concepts of materiality, reasonableness, good faith and fair dealing,
and we express no opinion herein with respect to provisions relating to severability or separability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">December 12, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page 4 of 4</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No opinion is expressed herein
as to any matter pertaining to the contents of the Registration Statement, other than as and to the extent expressly stated herein with
respect to the authorization and issuance of the Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This opinion is limited to
the specific issues addressed herein, and no opinion may be inferred or implied beyond that expressly stated herein. This opinion speaks
only as of the date of this letter, and we do not undertake by delivery of this opinion or otherwise to advise you of any change in any
matter set forth herein, whether based on a change in law (whether by legislative action, judicial decision, administrative decision or
otherwise) or a change in any fact arising subsequent to the date hereof that might affect any of the opinions expressed herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This opinion is furnished
for the benefit of the addressee hereof and for use solely in connection with the transactions contemplated by the Securities Purchase
Agreement and may not be used, circulated, quoted or otherwise relied upon for any other purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%">Very truly yours,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><I>/s/ FLANGAS LAW GROUP</I></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><B>FLANGAS LAW GROUP</B></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>ea022453701ex99-1_china.htm
<DESCRIPTION>PRESS RELEASE ANNOUNCING THE ENTRY OF THE AT-THE-MARKET EQUITY FINANCING
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>China Pharma Announces&nbsp;the Entry of &ldquo;At-The-Market&rdquo;
Equity Offering </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>HAIKOU CITY, December 13, 2024 &ndash; China
Pharma Holdings, Inc. </B>(NYSE American: CPHI) (&ldquo;China Pharma,&rdquo; or the &ldquo;Company&rdquo;), a specialty pharmaceutical company,
today announced that it has filed a prospectus supplement with the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;) under
which the Company may offer and sell from time to time shares of common stock, par value $0.001 per share (the &ldquo;Common Stock&rdquo;),
with an aggregate offering price of up to $600,000 (the &ldquo;Financing&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The shares will be offered pursuant to a certain
Securities Purchase Agreement (the &ldquo;SPA&rdquo;) the Company entered into with certain investor (the &ldquo;Investor&rdquo;) on December
12, 2024. Pursuant to the SPA, the Investor agrees to, at its discretion, purchase, from time to time over the commitment period from
December 12, 2024 through December 31, 2024, through one or more closings, up to $600,000 worth of the Common Stock, at the prices related
to prevailing market prices, which equals to the lower of (i) the closing price the day prior to the purchase notice, or (ii) the five
(5) day average closing prices of the Company as reported by Bloomberg or on the NYSE American Market&rsquo;s website and in accordance
with NYSE Rule Section 312.03(c), provided, in no event shall the price per share be lower than $0.15 per share. The timing of any sales
and the number of Common Stock sold, if any, will depend on a variety of factors to be determined by the Investor. There can be no assurance
that the Company will be able to issue and sell any Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The prospectus supplement filed today adds to,
updates or otherwise changes information contained in the accompanying prospectus contained in the Company&rsquo;s shelf registration
statement on Form S-3 (File No. 333-276481) filed by the Company with the SEC on January 12, 2024, as amended, and which became effective
on February 6, 2024. Prospective investors should read the prospectus in that registration statement and the prospectus supplement (including
the documents incorporated by reference therein) for more complete information about the Company and the Financing, including the risks
associated with investing in the Company. Copies of the prospectus supplement and related prospectus may be obtained from China Pharma
Holdings, Inc., Attn: Zhilin Li, 2nd Floor, No. 17, Jinpan Road, Haikou, Hainan Province, China 570216. You may also obtain these documents
free of charge when they are available by visiting EDGAR on the SEC&rsquo;s website at www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release shall not constitute an offer
to sell or a solicitation of an offer to buy, nor will there be any sale of these securities, in any state or jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Any offer, solicitation or sale will be made only by means of the prospectus supplement and the accompanying prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>About China Pharma Holdings, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">China Pharma
Holdings, Inc. is a specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products,
focusing on conditions with high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and
digestive diseases. The Company&rsquo;s cost-effective business model is driven by market demand and supported by new GMP-certified
product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network
across all major cities and provinces in China. The Company&rsquo;s wholly-owned subsidiary, Hainan Helpson Medical &amp;
Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please
visit http://www.chinapharmaholdings.com/ <FONT STYLE="text-decoration: none">The Company routinely posts important information on
its website.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Certain statements in
this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation
Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and
uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties
may include, but are not limited to: the achievability of financial guidance; success of new product development; unanticipated changes
in product demand; increased competition; downturns in the Chinese economy; uncompetitive levels of research and development; and other
information detailed from time to time in the Company&rsquo;s filings and future filings with the United States Securities and Exchange Commission.
The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update
any forward-looking statement to conform the statement to actual results or changes in the Company&rsquo;s expectations, except as required
by applicable law or regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>For more information, please contact Investor Relations:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">China Pharma Holdings, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ms. Diana Na Huang</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Phone: +86-898-6681-1730 (China)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email: hps@chinapharmaholdings.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>cphi-20241212.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +Kk5s7xRiXhun8uNbHcsWaODKaPtzp952YlBuGl+fUmKfyAj4/BOkSDaHlVmMUMG -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:CPHI="http://chinapharmaholdings.com/20241212" elementFormDefault="qualified" targetNamespace="http://chinapharmaholdings.com/20241212">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://chinapharmaholdings.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="cphi-20241212_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="cphi-20241212_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>cphi-20241212_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>cphi-20241212_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/Cover" xlink:href="cphi-20241212.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46473184881632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Dec. 12, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 12,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-34471<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CHINA PHARMA HOLDINGS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001106644<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">73-1564807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Second Floor<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">No. 17, Jinpan Road<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Haikou<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hainan Province<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">570216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">898-6681-1730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CPHI<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M.$#"WH8);R!.,D]^&4^><=+=2?6:;AG3Y#V.1-JSMEHG=[:=!EL6T_1:)DS
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M<F]P<R]A<' N>&UL4$L! A0#%     @ @T*-69'U0C/N    *P(  !$
M         ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ @T*-
M69E<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    " "#0HU9]B2DJVX$  "O$0  &
M@($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ @T*-
M69^@&_"Q @  X@P   T              ( !L0P  'AL+W-T>6QE<RYX;6Q0
M2P$"% ,4    " "#0HU9EXJ[',     3 @  "P              @ &-#P
M7W)E;',O+G)E;'-02P$"% ,4    " "#0HU9JL0B%C,!   B @  #P
M        @ %V$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ @T*-620>
MFZ*M    ^ $  !H              ( !UA$  'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ @T*-6660>9(9 0  SP,  !,
M     ( !NQ(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @
&!10

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea0224537-8k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>cphi-20241212.xsd</File>
    <File>cphi-20241212_lab.xml</File>
    <File>cphi-20241212_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ea0224537-8k_china.htm">ea0224537-8k_china.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0224537-8k_china.htm": {
   "nsprefix": "CPHI",
   "nsuri": "http://chinapharmaholdings.com/20241212",
   "dts": {
    "schema": {
     "local": [
      "cphi-20241212.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "cphi-20241212_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cphi-20241212_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ea0224537-8k_china.htm"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 24
   },
   "report": {
    "R1": {
     "role": "http://chinapharmaholdings.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-12",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0224537-8k_china.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-12",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0224537-8k_china.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001213900-24-108617-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-24-108617-xbrl.zip
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M74\;4GX*V<U%D**('D5=Q+>+F=JS,RT<=C9IC]@'\80V3"^U+$G,'6FEMHG
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MZL-_4Q,$ AW&C).22HJ4UL<+"8<I:]V_"%A[6P2L>Q8!ZQ 7 >NABX"UMT6
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M"NX*\*\RQ U'P963E69$N%8?SOB[\V.[/^*HD $)@U#KKNH6 %?1.;1;GEH
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MW0]ML$\Q&DMF.0B)Y:,XI^=[E$"MJ3AG&X1 %3)S:58.5==WO99ZU!3E7):
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M;G]__ZBWMP?G^X\GFT_HYY.CWJ[Y6:_W(@J+,_S.S9^^<IW710&'Q^9=(*Q
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MQ^^2U9&5J=&/P0OH:"+FUZCN_2*Q4W_I=W:+VJUIF4W3G)*=,8]M1X-6SS5
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M>L?+TV^M0IHFEDCCS;U17^5DQ)1)11,J0Q*!%R%9<I,.&BU>)VR96-'9L26
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MQ^NX>6/9\KG?Q+TTUYQR+3:?>^;-O]NZR;EJ-FO,.O=IN#O[..&R]QNVPE=
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M[@/&_9JIZCHD@ZW:8VKD"8'5LX.C*/-<)S+%QX0./F8%$($L]6[YX-+F2T8
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M,[0*S P'((VE 2D;W][9"N(7W']1779^0R;:!0A^2=;9)T1529<5'(@-IVB
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M[0[%%A_NQ2.:.IX#8O9%4?E_W*/-GB[7V_1O_ND_ =#_%?@W4$L! A0#%
M  @ @T*-6>"C>J0R P  ! P  !$              ( !     &-P:&DM,C R
M-#$R,3(N>'-D4$L! A0#%     @ @T*-6:XS'/[^"@  @(8  !4
M     ( !80,  &-P:&DM,C R-#$R,3)?;&%B+GAM;%!+ 0(4 Q0    ( (-"
MC5F,.,-N7@<  .M7   5              "  9(.  !C<&AI+3(P,C0Q,C$R
M7W!R92YX;6Q02P$"% ,4    " "#0HU9_!.%<O08   ,@0  %@
M    @ $C%@  96$P,C(T-3,W+3AK7V-H:6YA+FAT;5!+ 0(4 Q0    ( (-"
MC5D#5_.#M30  /Q^ 0 :              "  4LO  !E83 R,C0U,S<P,65X
M,2TQ7V-H:6YA+FAT;5!+ 0(4 Q0    ( (-"C5D4#G4GSQ$  /I2   :
M          "  3AD  !E83 R,C0U,S<P,65X-2TQ7V-H:6YA+FAT;5!+ 0(4
M Q0    ( (-"C5DGM\H>A0H  #(@   ;              "  3]V  !E83 R
M,C0U,S<P,65X.3DM,5]C:&EN82YH=&U02P4&      < !P#B 0  _8

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>ea0224537-8k_china_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cphi-20241212.xsd" xlink:type="simple"/>
    <context id="AsOf2024-12-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2024-12-12</startDate>
            <endDate>2024-12-12</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2024-12-12" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2024-12-12" id="Fact000004">0001106644</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2024-12-12" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2024-12-12" id="Fact000010">2024-12-12</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2024-12-12" id="Fact000011">CHINA PHARMA HOLDINGS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2024-12-12" id="Fact000012">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2024-12-12" id="Fact000013">001-34471</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2024-12-12" id="Fact000014">73-1564807</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2024-12-12" id="Fact000015">Second Floor</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2024-12-12" id="Fact000016">No. 17, Jinpan Road</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="AsOf2024-12-12" id="Fact000017">Haikou</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="AsOf2024-12-12" id="Fact000018">Hainan Province</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="AsOf2024-12-12" id="Fact000019">CN</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2024-12-12" id="Fact000020">570216</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2024-12-12" id="Fact000021">86</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2024-12-12" id="Fact000022">898-6681-1730</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2024-12-12" id="Fact000023">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2024-12-12" id="Fact000024">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2024-12-12" id="Fact000025">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2024-12-12" id="Fact000026">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2024-12-12" id="Fact000027">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2024-12-12" id="Fact000028">CPHI</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2024-12-12" id="Fact000029">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2024-12-12" id="Fact000030">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
